SCHEMBL3479688

SCHEMBL3479688

CN1CCN(c2ccc(Cl)c(Cl)c2)c2ccc(-c3ccc(=O)[nH]n3)cc2C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 5/20 0.49
SLC6A4 P31645 4/20 0.49
SLC6A3 Q01959 3/20 0.49
SCN9A Q15858 1/20 0.42
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
HRH3 Q9Y5N1 3/20 0.37
LMNA P02545 3/20 0.36
ALDH1A1 P00352 1/20 0.36
BCL2 P10415 1/20 0.36
MAPT P10636 1/20 0.36
ALOX12 P18054 1/20 0.36
BID P55957 1/20 0.36
RAD51 Q06609 1/20 0.36
BCL2L1 Q07817 1/20 0.36
BCL2A1 Q16548 1/20 0.36
BCL2L2 Q92843 1/20 0.36
KMT2A Q03164 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3479677 0.86 SCN9A (0.44) SLC6A2SLC6A4SLC6A3SCN9APDE4A
SCHEMBL3479716 0.85 SCN9A (0.47) SLC6A2SLC6A4SLC6A3SCN9APDE4A
SCHEMBL3234151 0.85 SCN9A (0.46) SLC6A2SLC6A4SLC6A3SCN9APDE4A
SCHEMBL3479922 0.84 SCN9A (0.44) SLC6A2SLC6A4SLC6A3SCN9APDE4A
SCHEMBL3479678 0.82 SLC6A2 (0.48) SLC6A2SLC6A4SLC6A3SCN9APDE4A
SCHEMBL3479414 0.81 SCN9A (0.46) SLC6A2SLC6A4SLC6A3SCN9APDE4A
SCHEMBL3231072 0.81 SCN9A (0.44) SLC6A2SLC6A4SLC6A3SCN9ALMNA
SCHEMBL3230829 0.81 SCN9A (0.42) SLC6A2SLC6A4SLC6A3SCN9ALMNA
SCHEMBL3479703 0.80 DRD2 (0.44) SLC6A2SLC6A4SLC6A3SCN9APDE4A
SCHEMBL3223902 0.78 SCN9A (0.46) SLC6A2SLC6A4SLC6A3SCN9AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096546-B2 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-08-04 US disclosed
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ALBANY MOLECULAR RESEARCH, INC. (US) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ADRA1B, ADRB1, ADRA1D SLC6A2 28/4885SLC6A4 40/4885SLC6A3 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.